Please login to the form below

Not currently logged in
Email:
Password:

China's Tasly to form pharma JV with UK Co-op group

Tasly Group, which is the parent of listed Tasly Pharmaceutical, has signed an agreement to form a pharmaceutical joint venture with the UK's Co-operative Group, in Tianjin in northern China.

Tasly Group, which is the parent of listed Tasly Pharmaceutical, has signed an agreement to form a pharmaceutical joint venture with the UK's Co-operative Group, in Tianjin in northern China.

According to a statement on the Tasley website, the venture's registered capital is USD 18m, with total investment expected to be in the region of USD 40m.

The new venture is slated to begin operations in 2009 with annual capacity of 200 millon pills and 200 million capsules. All the drugs manufactured by the plant will be exported to the EU market.

The tie up will give the Co-op, which operates more than 600 chemists in the UK and a pharmaceutical wholesaling business, greater control over its supply chain.

No further financial details were disclosed.

The Tasly Group was founded in 1994 and specialises in modern traditional Chinese medicine as well as scientific R&D and production. It is one of China's top three pharmaceutical suppliers, with a market value of around GBP 1.1bn (USD 2.2bn).

6th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics